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Host protective ASP-based vaccine 
against the parasitic nematode 
Ostertagia ostertagi triggers NK 
cell activation and mixed IgG1-IgG2 
response
Ana González-Hernández1, Stefanie Van Coppernolle1, Jimmy Borloo1, Frederik Van Meulder1, 
Oonagh Paerewijck1, Iris Peelaers1, Georges Leclercq2, Edwin Claerebout1 & Peter Geldhof1
The mucus-dwelling parasite Ostertagia ostertagi is one of the most important gastrointestinal 
nematodes in cattle. Our group has previously demonstrated the protective capacity of a vaccine 
against this parasite based on a native activation-associated secreted protein ASP1 (nASP) in 
combination with the saponin adjuvant QuilA. The aim of the current study was to analyse the effect 
of both antigen and adjuvant on the cellular and humoral vaccine-induced immune responses by 
comparing the native ASP to a recombinant version expressed in Pichia pastoris (pASP) and replacing 
QuilA by Al(OH)3. Immunization of cattle with the protective nASP+QuilA vaccine was associated 
with antigen-induced proliferation of natural killer (NK) cells combined with IFN-γ secretion and the 
induction of a mixed IgG1/IgG2 antibody response. ASP-specific activation and proliferation of NK 
cells was also observed in mice following the same vaccination regime. Replacing QuilA by Al(OH)3 or 
nASP by pASP significantly decreased the capacity of the vaccines to trigger both NK cell activation 
and antibody responses and failed to induce protection against a challenge infection. Reduction of 
the structurally anchoring disulphide bonds of the nASP completely abolished its ability to induce NK 
cell activation and antibody responses, highlighting the importance of protein conformation for the 
immunostimulatory activity.
Helminth infections pose a massive burden on human and animal health worldwide. Despite the widespread 
development of drug resistant worms, anthelmintic treatment still remains the main method to control these 
infections1,2. Vaccination strategies, either targeting the reduction in adult worm numbers present in the host 
or the reduction of worm fecundity, offer a promising alternative for anthelmintic treatment3,4. Nevertheless, 
hitherto only few vaccines against this type of pathogens are available. Two of the commercially available vaccines 
target the cattle and sheep lungworms Dictyocaulus viviparus5,6 and Dictyocaulus filaria7, respectively, and are 
based on whole irradiated larvae of these worms. Recently a promising vaccine against the blood feeding nema-
tode Haemonchus contortus in sheep, based on native antigens isolated from adult worms, was commercialized8. 
However, these examples of vaccines are exceptions. Due to the complex life cycle of helminths, there are many 
practical issues and high costs involved in the production of high quantities of these vaccines. Therefore, mim-
icking the protective response by recombinant antigens would provide a major breakthrough in parasite vaccine 
development. Although this approach has already proven successful for the production of protective vaccines 
against the cestodes Taenia saginata and Echinococcus granulosus9, and the nematode Teladorsagia circumcincta10, 
it has been unsuccessful in many other cases11.
In recent years, our research group has developed an experimental vaccine against the mucus dwelling abo-
masal nematode Ostertagia ostertagi in cattle12–18, which is based on activation-associated secreted proteins 
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(ASP). Intramuscular immunization of cattle with the native ASP (nASP) in combination with QuilA adjuvant 
raises an effective immune response, resulting in a significant reduction in faecal worm egg shedding of 56–74% 
during a two-month period17. A reduction in worm fecundity is typically the first manifestation of immunity 
against this parasite. Such decrease can significantly affect pasture infection levels and prevent parasitic gastroen-
teritis. A similar protective response is however not observed when the native antigen is replaced by a recombi-
nant version produced in insect cells14. Furthermore, replacing the QuilA adjuvant by Al(OH)3 has also shown to 
completely abolish the protective effect of the native antigen16, indicating that both the antigen and the adjuvant 
are essential to achieve protection. Understanding how immunity in animals, vaccinated with the nASP-QuilA 
vaccine, is orchestrated might help to identify the essential features that are needed to induce protection, infor-
mation which is crucial to direct future recombinant expression work. Previous research has shown that potential 
effector mechanisms involved in the vaccine-induced protection are antigen-specific IgG1 and IgG2 antibodies 
in the abomasal mucosa and increased levels of granule exocytosis, involving the local release of granulysin and 
granzyme B18. Information on the upstream mechanisms triggered by the vaccine and how these are influenced 
by antigen and adjuvant is still missing. Therefore, the overall aim of the present study was to analyse and compare 
the effect of both antigen (native vs recombinant) and adjuvant (QuilA vs Al(OH)3) on the cellular and humoral 
vaccine-induced immune responses.
Results
Vaccination with nASP+QuilA, but not pASP+QuilA or nASP+Al(OH)3, reduces worm egg 
production while increasing IgG1 and IgG2 antibody levels. Animals vaccinated in study 1 with the 
nASP+ QuilA vaccine showed a significant reduction of 59% in cumulative egg output compared to the control 
vaccinated group. This confirms our previous findings17. In contrast, no reduction of faecal egg counts (FEC) was 
observed following vaccination with pASP+ QuilA (Supplemental Fig. 1A). Similar to the observations made in 
study 1, animals from study 2 vaccinated with nASP+ QuilA vaccine showed a reduction of 42% in cumulative 
FEC compared with the control vaccinated group, whereas no reduction of FEC was observed in the pASP+ 
QuilA and nASP+ Al(OH)3 vaccinated groups (Supplemental Fig. 1B). For both studies, vaccination had no effect 
on worm counts (data not shown).
Vaccination with the nASP+ QuilA vaccine in study 1 resulted in a significant increase of nASP-specific IgG1 
and IgG2 levels in both serum and abomasal mucus samples compared to QuilA control animals (Fig. 1A,B). 
Vaccination with the pASP+ QuilA vaccine resulted in a significant increase of nASP-specific IgG1 levels in 
serum, whereas no significant changes were observed for cross-reactive systemic IgG2 and mucosal IgG1 and 
IgG2 levels (Fig. 1A,B). For study 2, nASP+ QuilA vaccinated animals had increased levels of nASP-specific IgG1 
in both serum and mucosa, whereas this effect was less pronounced for the pASP+ QuilA group and completely 
absent in the nASP+ Al(OH)3 group (Supplemental Fig. 2A,B). In contrast to the first study, vaccination had a 
smaller impact on the amount of nASP-specific IgG2 antibodies, both systemically and in the mucosa.
Vaccine-induced IgA’s were not detectable in the serum and there were no significant increases in mucosal 
nASP-specific IgA levels in both studies (data not shown).
Antibodies raised by the native and the recombinant vaccines differ in their binding properties. 
To evaluate the specificity of the antibodies raised by the nASP+ QuilA vaccine, an inhibition ELISA was per-
formed with serum samples collected one week after the last vaccination from nASP+ QuilA vaccinated animals. 
As shown in Fig. 2A, pre-incubation of the serum with pASP failed to completely inhibit the binding of the IgG1 
and IgG2 antibodies to nASP. In contrast, pre-incubation with nASP almost completely inhibited IgG1 and IgG2 
binding to nASP.
Vaccination of cattle with nASP+QuilA induces memory-like NK cells. In cattle study 2, periph-
eral blood mononuclear cells (PBMCs) were isolated on a weekly basis and used for phenotypical and functional 
analysis to measure antigen-specific proliferation in vitro. No vaccination-induced changes were observed in fre-
quencies of α β -T cells, γ δ -T cells, B cells or NK cells in the PBMC fraction (Supplemental Fig. 3A–D). However, 
when PBMCs were re-stimulated in vitro with the vaccine antigens, nASP for the nASP+ QuilA and nASP+ 
Al(OH)3 vaccinated animals and pASP for the pASP+ QuilA, antigen-specific proliferation was mainly found 
in the nASP+ QuilA group (Fig. 3A). Proliferation was the highest in the nASP+ QuilA vaccinated animals and 
became significantly different from control animals on weeks 2 and 4 after the first vaccination, with a decline 
thereafter (Fig. 3A). In the pASP+ QuilA vaccinated group, antigen-specific proliferation only became signifi-
cantly different from control animals one week after the first booster vaccination (Fig. 3A), but also here, a decline 
in proliferation was observed afterwards. Proliferation in the nASP+ Al(OH)3 vaccinated group (Fig. 3A) and in 
control animals (data not shown) was not significantly different throughout the whole vaccination period.
In order to determine whether in vitro re-stimulated PBMCs produced specific cytokines linked to either a 
Th1 or a Th2 type immune response, IFNγ levels were measured in culture supernatants produced by PBMCs 
isolated at week 5 and stimulated either with medium alone or with 5 μ g/ml of the vaccine antigen for five days. 
IFNγ levels were significantly higher in the culture supernatant of the cells from the nASP+ QuilA group, whereas 
no effect was observed for the other groups (Fig. 3B). There was no detectable IL-4 production after in vitro cul-
ture of PBMCs isolated from any group of animals with medium nor with the vaccine antigens (data not shown).
Next, to characterize the cellular immune response in the abomasum following vaccination and infection, 
abomasal lymph nodes (LNs) from all animals were obtained at the time of necropsy (i.e. five weeks after the onset 
of the trickle infection) for phenotypical analysis and proliferation assays. No statistical differences were found 
in the frequencies of α β -T cells, γ δ -T cells, B cells or NK cells in any vaccine protocol (Supplemental Fig. 4A–D). 
Similar to the observations made with PBMCs, there was a trend in higher proliferation following re-exposure 
in vitro in the group of animals that was vaccinated with the protective nASP+ QuilA vaccine (Fig. 3C), although 
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Figure 1. Detection of nASP-specific IgG1 and IgG2 antibodies in blood and mucosa after vaccination 
of cattle with nASP+QuilA and pASP+QuilA. In cattle study 1, (A) serum and (B) abomasal samples were 
collected from all animals and used for the detection of nASP specific IgG1 and IgG2 type antibodies through 
ELISA. The graphs show the individual and mean (± SEM) OD’s for each individual animal within each 
group ± SEM. Statistically significant differences are indicated with * p < 0.05.
Figure 2. Comparison of the interaction between antibodies raised against nASP with the native and 
recombinant ASP. (A) IgG1 and (B) IgG2 antibodies from calves vaccinated with nASP+ QuilA were evaluated 
in an inhibition ELISA. Graphs were generated from pooled samples in duplicate, where each point indicates 
the mean OD.
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4Scientific RepoRts | 6:29496 | DOI: 10.1038/srep29496
this did not reach statistical significance. These responding cells were subsequently characterized by isolating and 
labelling the abomasal LN cells of nASP+ QuilA vaccinated animals with PKH prior to in vitro re-stimulation 
with the nASP. As shown in Fig. 3D, proliferation was mainly detected in the CD335+ cell population, where 
CD335 expression is typically used to define NK cells.
Finally, immunohistofluorescence and immunohistochemical stainings were conducted on tissue sections 
from the abomasum. No significant differences in the numbers of T cells, B cells, macrophages, mast cells nor 
globular leukocytes were observed between the vaccinated groups and the control group (Supplemental Fig. 
5A–E). In addition, intraepithelial and lamina propria lymphocytes were isolated from the abomasum of all ani-
mals at the time of necropsy to determine the frequencies of α β -T cells, γ δ -T cells, B cells and CD335+ cells. No 
differences were observed in the frequencies of these cells between the different vaccinated groups (Supplemental 
Fig. 6A–D).
Vaccine-induced immune responses in a murine immunization model are similar to those 
observed in cattle. Based on the results obtained in cattle, we subsequently investigated whether the 
observed NK cell response following vaccination with the nASP+ QuilA vaccine was unique to cattle or whether 
Figure 3. Vaccination with nASP+QuilA triggers systemic nASP-specific IFNγ producing cells and 
mucosal NK cells. (A) During cattle study 2, peripheral blood mononuclear cells (PBMCs) were isolated 
weekly during the vaccination period and re-stimulated with either medium alone or the antigen used in the 
vaccine formulation. The arrows indicate the time points at which the animals were vaccinated. 3H-thymidine 
(3HT) uptake was used as a measure of proliferation. The graph shows the mean stimulation index ± SEM for 
all vaccinated groups. (B) Five weeks after the first vaccination, PBMCs from nASP+ QuilA, pASP+ QuilA and 
nASP+ Al(OH)3 groups were stimulated for 5 days with 5 μ g/ml nASP or pASP. IFNγ production of these cells 
was determined in the supernatants using an ELISA. The graph shows the mean concentration of IFNγ for each 
group ± SEM. (C) At time of necropsy, 5 weeks following the last vaccination, abomasal mononuclear cells 
(MNCs) were isolated, re-stimulated, and their proliferative capacity was measured as for the PBMCs. Mean 
stimulaton index ± SEM is shown for all groups. (D) Additional assays with PKH were performed on abomasal 
lumph nodes (LNs) to identify the proliferative populations of the nASP+ QuilA vaccinated group. After flow 
cytometric analysis, the proliferation results were calculated and presented as proliferation index. Statistically 
significant differences for all graphs are indicated with * p < 0.05.
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this would also be triggered in mice. To characterize the cellular immune response following vaccination in mice, 
spleen mononuclear cells (MNCs) were isolated at time of necropsy, and used for both 3H-thymidine (3HT) and 
PKH proliferation assays to determine antigen-specific proliferation in vitro. As observed in cattle, cells isolated 
from mice solely vaccinated with either QuilA or Al(OH)3 did not show any proliferation following in vitro 
stimulation with the nASP or pASP (Fig. 4A,E). Although significant proliferation was observed in cells from the 
pASP+ QuilA and nASP+ Al(OH)3 vaccinated animals following re-stimulation with the corresponding vaccine 
antigens (Fig. 4B,C,F), the highest proliferation was again observed in the nASP+ QuilA group. Furthermore, 
exposure of the cells from the pASP+ QuilA animals to nASP also resulted in a significant cellular proliferation 
in comparison to the medium control (Fig. 4C). Interestingly, cells from mice vaccinated with the nASP of which 
the disulphide bonds were reduced did not show any proliferation after re-stimulation with the reduced antigen 
(Fig. 4D).
Figure 4. Vaccination of mice with nASP+QuilA induces higher nASP-specific cell proliferation than 
other vaccine formulations. Mice were immunized three times in a 3-week interval intramuscularly in the 
thigh muscle and euthanized one week following the last vaccination. Mouse spleen MNCs were isolated 
and re-stimulated with either medium alone, nASP or pASP. 3HT uptake was used as a measure of total cell 
proliferation. All graphs show the mean counts per minute (CPM) ± SEM for animals vaccinated with (A) 
QuilA, (B) nASP+ QuilA, (C) pASP+ QuilA, (D) Reduced-ASP+ QuilA, (E) Al(OH)3 and (F) nASP+ Al(OH)3. 
Statistically significant differences are indicated with * p < 0.05.
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PKH assays were subsequently performed in order to characterize the proliferative cell populations. 
Confirming the 3HT assays (Fig. 4), Fig. 5 shows that there was no increased proliferation of cells from the QuilA 
and Al(OH)3 control groups nor from the reduced-nASP+ QuilA group upon in vitro stimulation with nASP, 
pASP or reduced-nASP (Fig. 5A,D,E). On the other hand, B cells, and especially NK and non-T, non-B non-NK 
cells (CD3−/CD21−/CD335−) from nASP+ QuilA vaccinated mice showed significant proliferation after in vitro 
re-stimulation with nASP compared to cells stimulated with medium alone (Fig. 5B). Antigen-specific prolifer-
ation of the NK and non-T, non-B non-NK cells (CD3−/CD21−/CD335−) following re-stimulation with nASP 
was also observed with cells from the pASP+ QuilA and nASP+ Al(OH)3 groups (Fig. 5C,F), albeit at a lower level 
compared to the nASP+ QuilA group. When re-stimulating cells from the nASP+ Al(OH)3 group with nASP, 
Figure 5. NK cells and CD3−/CD21−/CD335− cells are the main vaccine-induced proliferative cell 
populations in mice. Mouse spleen MNCs were isolated and re-stimulated for 5 days with either medium 
alone, nASP or pASP and stained with monoclonal antibodies for further FACS analysis. PKH incorporation 
to the membrane and its further dilution was used as a measure of cell proliferation. All graphs show the mean 
proliferation index (PI) ± SEM for animals vaccinated with (A) QuilA, (B) nASP+ QuilA, (C) pASP+ QuilA, (D) 
Reduced-ASP+ QuilA, (E) Al(OH)3 and (F) nASP+ Al(OH)3. Statistical differences are indicated with * p < 0.05.
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modest levels of γ δ -T cell proliferation could also be observed (Fig. 5F). Finally, re-stimulation of pASP+ QuilA 
cells with pASP induced antigen-specific NK cells proliferation, which was similar to that observed after nASP 
stimulation, but again much lower than the levels observed in the nASP+ QuilA group (Fig. 5C).
At the time of necropsy, all mice were bled from the retro-orbital vein and the serum was used to measure 
antigen specific IgG1, IgG2a and IgG2b levels by enzyme-linked imminosorbent assay (ELISA), essentially as 
described for cattle. The levels of nASP-specific IgG1 antibodies were significantly higher in animals vaccinated 
with nASP+ QuilA, pASP+ QuilA and nASP+ Al(OH)3 (Fig. 6A) compared to their respective controls. No sig-
nificant increase in antigen-specific IgG1 levels could be detected in the reduced-nASP+ QuilA and Al(OH)3 
immunized animals. While no significant levels of nASP-specific IgG2a could be detected in any of the groups 
(data not shown), IgG2b antibodies were significantly higher in animals vaccinated with nASP+ QuilA and 
pASP+ QuilA when compared to the QuilA controls, whereas no significant increase could be observed for the 
other groups (Fig. 6B).
Discussion
NK cells were the major cell population found in nASP+ QuilA vaccinated animals which proliferated follow-
ing re-stimulation of MNCs from the abomasal draining LN or spleen of cattle and mice, respectively. NK cells 
are large granular lymphocytes that either become directly activated by pathogens or through interaction with 
other pathogen-activated immune cells. They were originally named after their ability to spontaneously kill trans-
formed, infected or non-self cells without prior sensitization or activation. Despite their innate origin, there 
is accumulating evidence that also NK cells can develop long-lived and highly specific memory to a variety of 
antigens19–21. Previous studies also indicate that NK cells are likely to be involved in the natural immune response 
in cattle following nematode infection. It was already shown that NK cells are important in the proliferation 
observed in the abomasal lymph nodes during the course of an infection22,23. More recently, an antigen-specific 
proliferation of NK cells was observed in the draining lymph nodes of the small intestine of animals infected 
with C. oncophora24. Also, analysis of transcriptional changes by qRT-PCR in the abomasal mucosa following 
Ostertagia infection showed a significant upregulation of the NK cell marker CD33525 and the expression of gran-
ulysin and granzyme, both proteins that are typically produced by NK cells18. Furthermore, the flow cytometric 
analyses performed in this study showed that NK cells represented roughly 15% of the total abomasal lymphocyte 
population following infection.
The observed NK cell activation and IFNγ production following in vitro re-stimulation with the native ASP 
is also in line with previously published data on an ASP (rOv-ASP-1) from the filarial parasite Onchocerca vol-
vulus. In a series of papers, it was shown that immunisation with Ov-ASP-1 induced a highly dominant IFN-γ 
recall response following vaccination, most likely produced by activated NK cells, combined with a mixed IgG1/
IgG2 antibody reaction26–28. Similar to the O. ostertagi ASP, the bioactivity of Ov-ASP-1 was completely lost after 
denaturing the protein by boiling26. It is also interesting to note that secreted protein(s) of the human hookworm 
Necator americanus selectively bind to NK cells and induced IFN-γ production and that this process is dependent 
on the presence of the cytokines IL-2 and IL-12, likely secreted by activated antigen-presenting cells29,30. Whether 
ASPs are responsible for this activity is currently unknown.
Figure 6. Detection of nASP-specific IgG1 and IgG2b antibodies in blood after vaccination of mice with 
different vaccine formulations. Mice serum was collected at time of necropsy and used for the detection  
of nASP specific (A) IgG1 and (B) IgG2b type antibodies through ELISA analysis. The graph shows the OD 
for each individual animal within each group ± SEM. Statistical differences are indicated with * p < 0.05,  
* * p < 0.005, * * * p < 0.001, * * * * p < 0.001.
www.nature.com/scientificreports/
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Teixeira-Carvalho et al.30 previously hypothesized that the activation of NK cells and IFN-γ production is 
part of an immune evasion strategy by the worms, in an attempt to down-regulate a protective Th2 response29. 
In case of the O. ostertagi vaccine it is unclear whether the NK cell activation is necessary to obtain protection or, 
alternatively, whether the protective capacity of the vaccine is based on the generation of antibodies, potentially 
interfering with the immunomodulatory activity of the ASP. Over the years, several studies have demonstrated 
that antibodies can provide protective immunity against gastrointestinal helminths in a direct and/or indirect 
way31. This protection would hypothetically be achieved through antibody-dependent activation of immune cells 
in the intestinal mucosa, or by interfering with enzymes and processes required for larval migration, invasion 
and feeding. In that context, nASP+ QuilA vaccinated cattle had an increased amount of nASP-specific IgG1 and 
IgG2-type antibodies both in blood and in the abomasal mucus. Interestingly, NK cells express Fcγ RIII (CD16) 
at their surface, which can mediate antibody-dependent cytotoxicity through the recognition of sequestered anti-
gens32. NK cells are highly abundant in the intraepithelial and lamina propria lymphocyte fractions of the abo-
masum, creating a high chance for effective contact between their CD335+ receptor and the different parasitic 
life stages of O. ostertagi. Therefore, a possible mechanism of action for NK cells against O. ostertagi could be the 
recognition of antibody-sequestered nASP and subsequent antibody mediated degranulation. Since NK cells are 
known to express granzyme B, perforin and granulysin, this could be an interesting link with previous observa-
tions on the upregulation of granulysin and granzyme B in animals protected by vaccination against O. ostertagi18.
The cellular and humoral responses observed for the protective nASP+ QuilA vaccine were markedly higher 
compared to responses observed for the non-protective nASP+ Al(OH)3 vaccine, both in cattle and mice. The 
exact mechanisms by which both adjuvants act are not completely understood yet. It has been shown that 
Al(OH)3 exerts a reservoir function, from which antigen is released slowly for a prolonged period of time33, 
whereas saponin-based adjuvants such as QuilA exert a more cytolytic function34. Despite the fact that Al(OH)3 is 
regarded as a Th2 type immune response inducing adjuvant, saponin-based adjuvants seem to induce a stronger 
antibody response against the vaccine antigen than Al(OH)335, supporting the hypothesis of a possible important 
role for antibodies in the vaccination-induced protection against O. ostertagi. Additionally, not only the choice of 
adjuvant, but also the conformation of the antigen has proven to be essential in triggering a protective immune 
response. Unfolding the ASP completely abolished its ability to induce both NK cell activation and antibody 
induction. Furthermore, we also showed that the recombinant version of the ASP, expressed in P. pastoris, was 
less potent in triggering both a cellular and humoral response. These observations indicate that protein folding, 
potentially in combination with N- and/or O-glycans present on the peptide core, of the native ASP is crucial for 
its immunoreactivity and that these factors could be at the basis of the inability of recombinant ASP in triggering 
a similar response. This is in line with the results of inhibition ELISA’s showing that antibodies raised upon nASP 
vaccination preferentially bind nASP over pASP, suggesting the presence of either different and/or additional 
epitopes.
In conclusion, the outcome of this study indicates that immunization of animals with the protective nASP+ 
QuilA vaccine is associated with antigen-induced proliferation of NK cells and the production of antigen-specific 
IgG1 and IgG2 antibodies. Replacing either: i) the native antigen by a recombinantly produced version or, ii) the 
QuilA adjuvant by Al(OH)3 both had a significant impact on the cellular and humoral vaccine-induced responses. 
Whether NK cells and antibodies are actually essential for conferring protection against an O. ostertagi challenge 
infection remains unknown. Also, the molecular and cellular mechanisms underlying the NK cell activation and 
the structural elements of the nASP that are crucial in this process require further research.
Materials and Methods
Native and recombinant antigen production. For the production of nASP, helminth‐naive calves were 
infected with 200,000 O. ostertagi infective larvae (L3) and euthanized 3 weeks later to collect adult worms from 
the abomasum. Adult worms were cultured, and excretory-secretory proteins collected from the culture superna-
tant as previously described17. The ASP sub‐fraction was purified from total adult ES material by thiol-sepharose 
chromatography, followed by anion exchange chromatography17. The protein profile of the obtained material 
was checked by separation on a 10% SDS-PAGE gel under reducing/denaturing conditions and visualized by 
Coomassie blue staining. Reduction of nASP was achieved by incubating nASP with 7.5 mM dithiothreitol (DTT) 
for 15 minutes at 60 °C. Afterwards, the nASP was incubated in iodo acetamide (IAA) at 37 °C for an additional 
30 minutes followed by a dialysis against 150 mM phosphate-buffered saline (PBS).
Recombinant ASP was produced in Pichia pastoris as previously described36 and will be referred to as pASP.
Immunization experiments in cattle. All animal experiments were conducted in accordance with the 
E.U. Animal Welfare Directives and VICH Guidelines for Good Clinical Practice, and ethical approval to conduct 
the studies were obtained from the Ethical Committee of the Faculty of Veterinary Medicine, Ghent University 
(EC2009/105, EC 2011/183). Two vaccination studies were carried out in cattle, essentially as previously 
described13,16. The aim of study 1 was to analyse and compare the humoral responses induced by the native and 
recombinant antigens in combination with QuilA. Twenty-one male crossbreed Holstein calves (6 to 8 months 
of age) were randomly divided over three groups of 7 animals (QuilA control, pASP+ QuilA and nASP+ QuilA). 
A second study was performed to analyse and compare the cellular responses induced by the different versions 
of the vaccine, i.e. nASP+ QuilA, pASP+ QuilA, nASP+ Al(OH)3, in comparison to control animals vaccinated 
with PBS. For this study, a Holstein crossbreed population of 16 male helminth-free calves (6 to 8 months of age) 
was randomly divided into four groups of four animals (PBS control, nASP+ QuilA, pASP+ QuilA and nASP+ 
Al(OH)3). For both studies, all animals were immunized three times intramuscularly in the neck with a 3-week 
interval. Control animals received either 750 μ g of QuilA (study 1) or 1 ml of PBS (study 2) per immunization, 
while the animals of the nASP+ QuilA, pASP+ QuilA and nASP+ Al(OH)3 groups received 30 μ g of antigen in 
combination with either 750 μ g of QuilA or an equal volume of Al(OH)3 adjuvants (both from Superfos Biosector, 
www.nature.com/scientificreports/
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Denmark) per immunization. All animals were challenged with a trickle infection of 25,000 L3 larvae (1000 L3/
day; 5 days/week, during 5 weeks), which started at the day of the third immunization. Calves from study 1 were 
euthanized 3 weeks after the last infection, while the animals from study 2 were euthanized immediately after 
the last infection. Parasitological parameters (i.e. FEC and worm counts) were analysed as described in previous 
trials13,16. Additionally, in study 2, abomasal LNs, abomasal epithelium and lamina propria were also isolated at 
time of necropsy.
Immunization experiments in mice. All animal experiments were conducted in accordance with the 
E.U. Animal Welfare Directives and VICH Guidelines for Good Clinical Practice, and ethical approval to conduct 
the studies were obtained from the Ethical Committee of the Faculty of Veterinary Medicine, Ghent University 
(EC 2014/33 and EC 2014/104). Thirty-six 8-week-old C57BL/6N mice (Harlan laboratories) were divided into 
6 groups of 6 animals each and immunized three times in a 3-week interval intramuscularly in the thigh mus-
cle. Control groups received 20 μ g of QuilA or Al(OH)3 (same volume as used in the antigen-vaccinated group) 
per immunization. Groups that included antigen in the vaccine formulation received either 5 μ g of nASP, pASP 
or reduced-nASP in combination with 20 μ g of QuilA adjuvant, while the last group received 5 μ g of nASP in 
combination with an equal volume of Al(OH)3 per immunization. At time of necropsy (one week after the third 
immunization), spleens and blood from the retro-orbital vein were collected for cellular and humoral analyses.
Isolation of mononuclear cells. For cattle, PBMCs were isolated weekly from blood by Lymphoprep 
(Nycomed Pharma) gradient centrifugation. Lymph node MNCs were isolated from the draining LNs of the 
abomasum by homogenization through mechanical disruption of the tissue followed by a Lymphoprep gradient 
centrifugation. Mucosal MNCs were isolated by removing the mucus from the abomasum and separating the 
mucosa from the submucosa. The mucosa was then cut into pieces of approximately 1 cm and extensively washed 
in Calcium and Magnesium free (CMF) HBSS (Invitrogen) containing 2 mM DTT (Biosolve). The DTT was 
removed by washing the tissue with CMF HBSS, after which the tissue was incubated for 30 minutes at 37 °C in 
CMF HBSS containing 5mM EDTA (Invitrogen), while gently stirring. The cells in the supernatant were collected 
and washed with CMF HBSS. The remaining tissue was washed with CMF HBSS and afterwards minced into 
small pieces of approximately 2 mm and digested with 2 mg/ml collagenase (Invitrogen) for 1 hour at 37 °C, while 
gently stirring. The cells in the supernatant were collected and washed with CMF HBSS and added to the cell pel-
let that was obtained earlier (see above). All cells were resuspended in 40% Percoll (GE Healthcare) and layered 
over a 62% Percoll layer. After centrifugation, all mononuclear cell fractions were isolated, washed and counted 
prior to cell culture or flow cytometric analysis.
To isolate MNCs from mice, spleens were removed, mechanically disrupted and homogenized, and passed 
through a 70 μ m cell strainer (BD Biosciences). Erythrocytes were lysed with ACK lysing buffer (Invitrogen) and 
remaining cells were washed and counted prior to cell culture or flow cytometry analysis.
Antibodies and Flow Cytometry. Cells were labelled in PBS containing 1% Bovine Serum Albumin 
(BSA), 0.1% Na-azide (both from Sigma-Aldrich) and the antibodies at the concentration recommended by the 
supplier. After an initial incubation of 20 minutes, the cells were washed and, whenever necessary, subsequently 
stained with fluorescently labelled secondary antibodies at the concentration recommended by the supplier. The 
cells were then incubated for 20 minutes prior to washing and resuspension in PBS, and immediately analysed 
using either FACS Canto or FACS Aria III flow cytometers (BD Biosciences). Non-viable cells were excluded of 
the analysis based on their propidium iodide (Molecular Probes) uptake.
Primary antibodies used in cattle were: non-labeled CD3 (MM1A, IgG1), TCRγ δ (GB21A, IgG2b), CD21 
(BAQ15A, IgM) (all from VMRD) and Alexa Fluor 488-labeled CD335 (AKS1, IgG1, AbD Serotec). Secondary 
antibodies used were: goat anti-mouse IgG1-FITC (Santa Cruz Biotechnology), goat anti-mouse IgG2a-APC 
(Invitrogen), rat anti-mouse IgG1-APC (BD Biosciences), rat anti-mouse IgG2b-FITC (Southern Biotech), rat 
anti-mouse IgM-APCCy7 (Biolegend) and goat anti-mouse IgG2a- PE (Invitrogen).
Antibodies used for mice were: CD3-PECy7 (clone 145-2C11), CD4-Biotin (clone RM4-5) and CD8a-PECy7 
(clone 53-6.7) from eBioscience, and CD3-APC (clone 145-2C11), CD335-AlexaFluor647 (clone 29A1.4), 
CD19-Biotin (clone 1D3) and TCRγ δ -FITC (clone GL3) from BD Biosciences. Biotin-conjugated antibodies were 
fluorescently labelled using streptavidin-APC-eFluor780 (eBioscience).
Proliferation assays. The MNCs collected from mice and cattle were used in proliferation assays using 
either 3H-thymidine incorporation or PKH (Sigma-Aldrich) fluorescence intensity reduction as a read-out. For 
3HT uptake experiments, 2.5 × 105 cells were loaded per well in a 96-well round bottom plate (Thermo Scientific) 
in 200 μ l of complete medium composed of RPMI 1640 + GlutaMAX (Invitrogen) supplemented with 50 μ g/ml 
Gentamycin (Invitrogen), 50 μ M β -mercaptoethanol (Sigma-Aldrich) and 10% fetal calf serum (Moregate). Each 
well was either stimulated with medium alone, 5 μ g/ml nASP, 5 μ g/ml pASP or 1 μ g/ml ConA (Sigma-Aldrich), 
which served as positive control. Each condition was performed in triplicate. After 4 days of culture (cattle) or 
5 days of culture (mice), cells were pulsed with 1 μ Ci 3HT (Perkin Elmer). After an additional 18 hours of cul-
ture, cells were harvested and analysed with a 1450 Microbeta β -scintillation counter (Perkin Elmer). Results are 
shown as stimulation index (SI), which is the ratio of the counts per minute of cells cultured with the vaccine 
antigen and the counts per minute of cells cultured with medium alone, or as counts per minute (CPM).
For the PKH experiments, cells were labelled with PKH26 (Sigma-Aldrich) according to the manufacturer’s 
instructions with the only difference that PKH26 was used at a dilution of 1/125. After labelling, a small fraction 
of the cells was used for flow cytometric analysis to determine the starting intensity of PKH. The rest of the cells 
were seeded at 2.5 × 105 cells/200 μ l RPMI complete medium (cattle) or at 5 × 105 cells/200μ l RPMI complete 
medium (mice) in 96-well round bottom plates, either stimulated with medium alone, 5 μ g/ml nASP or 5 μ g/ml 
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pASP. After 5 days of culture, the cells were harvested, stained with monoclonal antibodies and analysed by flow 
cytometry. ModFit LT software (Verity Software House) was used to calculate the proliferation index for the dif-
ferent cell populations, based on the PKH data.
In order to measure cytokine production during the proliferation of bovine PBMCs, blood was collected 2 
weeks after the second vaccination in study 2 and PBMCs were cultured in 24-well plates (BD Bioscience) at 
1 × 106 cells/ml in RPMI complete medium and re-stimulated in vitro with medium alone or 5 μ g/ml of nASP for 
the nASP+ QuilA, nASP+ Al(OH)3 and PBS groups, or pASP for the pASP+ QuilA group. After 5 days of culture, 
supernatants were harvested and used on an ELISA. IFNγ and IL4 capture monoclonal antibodies were coated in 
carbonate buffer (pH 9.6) on 96-well Maxisorp (Nunc) plates at a concentration of 2 μ g/ml and 4 μ g/ml, respec-
tively. Plates were blocked with 2% BSA in PBS for one hour at room temperature. Afterwards, 50 μ l of superna-
tant was administered to each well, and medium with a known concentration of either bovine IFNγ or IL4 was 
used as a standard. All conditions were performed in duplicate. Biotinylated monoclonal antibodies raised against 
IFNγ or IL4 (kindly provided by Prof. Jayne Hope, The Roslin Institute, UK) were added at a concentration of 
2 μ g/ml. Streptavidin-horseradish-peroxidase (Sigma-Aldrich) was used as a conjugate. O-phenylenediamine 
(Sigma-Aldrich) 0.1% in citrate buffer (pH 5.0) served as substrate. Optical density was measured at 492 nm. OD 
values were converted to concentrations using Deltasoft JV software (Deltasoft).
Histology and cell counts. Abomasal tissue samples from the calves used in study 2 were collected and 
used for histochemical and immunostainings as previously described18. Globular leukocytes and mast cells were 
identified using Sirius Red staining (Polysciences inc.) and a Toluidine Blue staining (Sigma-Aldrich), respec-
tively. The primary antibodies used for immunostainings were rabbit polyclonal anti-human CD3 (Dako), rab-
bit polyclonal anti-human CD20 (Thermo Scientific) and mouse IgG1 anti-human MAC387 (AbD Serotec). 
Secondary antibodies used were goat anti-rabbit IgG-biotin (Dako) or Goat anti-mouse IgG-biotin (Dako), 
diluted in PBS 2% BSA, according to the manufacturer’s instructions. Afterwards, sections were stained with the 
peroxidase-streptavidine complex (Dakocytomation A/S), diaminobenzidine tetrahydrochloride (DAB, Sigma–
Aldrich) and H2O2 (Calbiochem) followed by counterstaining with haematoxylin. All sections were mounted in 
synthetic medium DPX prior to analysis.
B cells (CD20), T cells (CD3) and macrophages (MAC387) were quantified by taking 4 random pictures per 
tissue slide at 200x magnification and calculating the number of cells per mm2 tissue surface. Quantification of 
globular leucocytes and mast cells was carried out by counting the number of Sirius Red or Toluidine blue positive 
cells, respectively, present in 8 random fields of view per tissue slide at 400-x magnification. Cell counts were con-
ducted for all animals of each group of vaccinated and infected animals. The results are expressed as cells/mm2.
ELISA. For cattle, the systemic and abomasal IgG1, IgG2, and IgA levels against O. ostertagi nASP were deter-
mined by ELISA. nASP was coated in 96-well Maxisorp plates (Nunc) at a concentration of 0.5 μ g/ml in carbonate 
buffer (pH 9.6). After 1 h blocking with 2% BSA-PBS at room temperature, either 100 μ g mucus extract in PBS 
or 100 μ l of a 1/200 serum dilution were administered in duplicate and incubated for an additional hour. After 
washing 3 times with 0.05% Tween 20-PBS, sheep anti-bovine IgG1, IgG2 and IgA (AbD Serotec) coupled to HRP 
were used as conjugates (dilution 1/500). O-phenylenediamine 0.1% in citrate buffer (pH 5.0) served as substrate. 
Optical density was measured at 492 nm.
The antibody responses in mice were measured by coating 96-well Maxisorp plates with nASP at a concen-
tration of 5 μ g/ml in carbonate buffer (pH 9.6). Following blocking with 2% BSA-PBS, 100 μ l of a 1/200 serum 
dilution (were tested in duplicate. After washing 3 times with 0.05% Tween 20-PBS, rabbit anti-mouse IgG1, 
IgG2a (dilution 1/2000) and IgG2b (dilution 1/1000)(Sigma-Aldrich) and rat anti-mouse IgE (dilution 1/1000), 
all coupled to HRP, were used as conjugates and 2,2′ -azinobis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) in 
ABTS buffer (Roche) was used as substrate. Optical density was measured at 405 nm.
An inhibition ELISA assay was subsequently designed to evaluate the specificity of the antibodies raised in 
cattle. Serum samples from the nASP+ QuilA vaccinated animals from study 1 were collected at one week after 
the final vaccination and used in an inhibition ELISA assay. Serum samples from all animals were pooled, diluted 
1/200 and subsequently incubated for 1 h at room temperature with different concentrations of either nASP or 
pASP, ranging from 0 up to 500 pmol/ml, before being analysed by ELISA as described above.
Statistical analysis. Statistical analyses were carried out using GraphPad Prism software. A non-parametric 
Kruskal-Wallis test was used to determine significant differences in parasitological parameters, cytokine pro-
duction, antibody responses, cattle 3HT assays and cell frequencies between vaccinated and control groups. For 
the cattle 3HT assays, an additional ANCOVA (SPSS, IBM SPSS statistics version 23.0) was used to test correla-
tion between weeks with no significant results. To determine significant differences in proliferation between the 
various cell subsets in the cattle abomasal MNCs and mice spleen MNCs, non-parametric Wilcoxon test was 
used. Finally, a non-parametric Friedman test was used to determine the statistical significance of the 3HT assays 
performed in mice where more than two groups were involved. A P-value of ≤ 0.05 was considered significant.
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